Patient advocacy groups take in millions from drugmakers. Is there a payback? Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
AstraZeneca has received a double boost for its oncology portfolio after US and European regulators accepted regulatory submissions for its drugs.
Pfizer has revealed this week that it intends to take a 25% stake in Allogene Therapeutics, in order to accelerate the development of CAR-T cell therapies sources from donors instead of patients.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
Searching for new drugs requires patience, skill and, of course, money. Now, researchers have developed a method to examine millions of potential self-produced drug candidates in one go.
Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.